The Food and Drug Administration has issued warning letters to 30 telehealth companies over "false or misleading claims" about compounded GLP-1 weight-loss drugs, the most aggressive enforcement action yet in a battle over who gets to sell America's most sought-after medications [1].

Compounded versions of semaglutide and tirzepatide — the active ingredients in Ozempic, Wegovy, and Mounjaro — have flourished through telehealth platforms that offer them at a fraction of the brand-name cost. The FDA's crackdown targets both the marketing claims and what it calls "illegal" sales of unapproved formulations [2].

The agency's position is straightforward: compounded drugs are not FDA-approved, their quality is not guaranteed, and patients may receive inconsistent doses. Novo Nordisk and Eli Lilly, which manufacture the brand-name versions, have lobbied aggressively for the crackdown [3].

But patients tell a different story. For millions of Americans without insurance coverage for brand-name GLP-1s — which can cost over $1,000 per month — compounded alternatives available through telehealth for $200-$400 were the only affordable option. The FDA's "thousands" of warning letters, as the agency described its broader campaign, threaten to close that door [4].

The legal landscape is evolving quickly. At least one compounder has sued Lilly and Novo Nordisk, claiming coordinated efforts to eliminate competition. The FDA, meanwhile, has signaled it intends to act against non-approved GLP-1 drugs regardless of shortage status [5].

-- Nora Whitfield, Chicago